FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386998412> ?p ?o ?g. }

• W4386998412 endingPage "3824" @default.
• W4386998412 startingPage "3813" @default.
• W4386998412 abstract "Abstract We investigated whether T cell-recruiting bispecific anti-CD3/GD2 antibody NG-CU might be an alternative to therapeutic anti-GD2 monoclonal antibody (mAb) ch14.18, mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer (NK) cells for immunotherapy in high-risk/relapsed neuroblastoma after autologous/allogeneic stem cell transplantation (auto/alloSCT). Different antibody concentrations and effector-to-target ratios ( E:T ) were evaluated using xCELLigence RTCA system, peripheral blood mononuclear cells (PBMCs) (healthy donors and patients after alloSCT), and neuroblastoma cell lines (LS/LAN-1). Mean specific lysis of LS cells utilizing PBMCs from healthy donors and ch14.18 (1 µg/ml) was 40/66/75% after 12/24/48 h compared to 66/93/100% in the presence of NG-CU (100 ng/ml). NG-CU showed enhanced cytotoxicity compared to ch14.18, even at lower concentrations and E : T ratios, and completely eradicated LS cells after 72 h. To decipher the influence of effector cell subsets on lysis, different ratios of T and NK cells were tested. At a ratio of 1:1, ch14.18 was more effective than NG-CU. Using patient PBMCs taken at different time points posttransplant, significant lysis with both constructs was detectable depending on percentages and total numbers of T and NK cells; in the early posttransplant phase, NK cells were predominant and ch14.18 was superior, whereas later on, T cells represented the majority of immune cells and NG-CU was more effective. Our study highlights the importance of analyzing effector cell subsets in patients before initiating antibody-based therapy. Consequently, we propose an adjusted administration of both antibody constructs, considering the state of posttransplant immune recovery, to optimize anti-tumor activity." @default.
• W4386998412 created "2023-09-25" @default.
• W4386998412 creator A5006156299 @default.
• W4386998412 creator A5016523064 @default.
• W4386998412 creator A5020950464 @default.
• W4386998412 creator A5035626095 @default.
• W4386998412 creator A5037246404 @default.
• W4386998412 creator A5039523731 @default.
• W4386998412 creator A5061269411 @default.
• W4386998412 creator A5066615137 @default.
• W4386998412 creator A5085043223 @default.
• W4386998412 creator A5089434867 @default.
• W4386998412 creator A5092931211 @default.
• W4386998412 creator A5092931212 @default.
• W4386998412 date "2023-09-24" @default.
• W4386998412 modified "2023-10-16" @default.
• W4386998412 title "Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)" @default.
• W4386998412 cites W1794874335 @default.
• W4386998412 cites W1954768511 @default.
• W4386998412 cites W1965505894 @default.
• W4386998412 cites W1969208169 @default.
• W4386998412 cites W1991644988 @default.
• W4386998412 cites W1991718860 @default.
• W4386998412 cites W1996695338 @default.
• W4386998412 cites W2009523265 @default.
• W4386998412 cites W2016589035 @default.
• W4386998412 cites W2020634797 @default.
• W4386998412 cites W2026537544 @default.
• W4386998412 cites W2036571548 @default.
• W4386998412 cites W2037618686 @default.
• W4386998412 cites W2047080123 @default.
• W4386998412 cites W2065347473 @default.
• W4386998412 cites W2066925870 @default.
• W4386998412 cites W2067216204 @default.
• W4386998412 cites W2073026109 @default.
• W4386998412 cites W2088282752 @default.
• W4386998412 cites W2089460727 @default.
• W4386998412 cites W2090728148 @default.
• W4386998412 cites W2095296988 @default.
• W4386998412 cites W2100033620 @default.
• W4386998412 cites W2118241155 @default.
• W4386998412 cites W2130465135 @default.
• W4386998412 cites W2141612652 @default.
• W4386998412 cites W2147068163 @default.
• W4386998412 cites W2171696371 @default.
• W4386998412 cites W2327522594 @default.
• W4386998412 cites W2416050694 @default.
• W4386998412 cites W2592061165 @default.
• W4386998412 cites W2752617269 @default.
• W4386998412 cites W2782402813 @default.
• W4386998412 cites W2805565362 @default.
• W4386998412 cites W2900463817 @default.
• W4386998412 cites W3004101682 @default.
• W4386998412 cites W3037009138 @default.
• W4386998412 cites W3112580059 @default.
• W4386998412 cites W3114897925 @default.
• W4386998412 cites W3168484605 @default.
• W4386998412 cites W3186320715 @default.
• W4386998412 cites W4200441628 @default.
• W4386998412 cites W4287578662 @default.
• W4386998412 cites W4322623407 @default.
• W4386998412 cites W4378516722 @default.
• W4386998412 cites W4386284174 @default.
• W4386998412 doi "https://doi.org/10.1007/s00262-023-03536-x" @default.
• W4386998412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37742286" @default.
• W4386998412 hasPublicationYear "2023" @default.
• W4386998412 type Work @default.
• W4386998412 citedByCount "0" @default.
• W4386998412 crossrefType "journal-article" @default.
• W4386998412 hasAuthorship W4386998412A5006156299 @default.
• W4386998412 hasAuthorship W4386998412A5016523064 @default.
• W4386998412 hasAuthorship W4386998412A5020950464 @default.
• W4386998412 hasAuthorship W4386998412A5035626095 @default.
• W4386998412 hasAuthorship W4386998412A5037246404 @default.
• W4386998412 hasAuthorship W4386998412A5039523731 @default.
• W4386998412 hasAuthorship W4386998412A5061269411 @default.
• W4386998412 hasAuthorship W4386998412A5066615137 @default.
• W4386998412 hasAuthorship W4386998412A5085043223 @default.
• W4386998412 hasAuthorship W4386998412A5089434867 @default.
• W4386998412 hasAuthorship W4386998412A5092931211 @default.
• W4386998412 hasAuthorship W4386998412A5092931212 @default.
• W4386998412 hasBestOaLocation W43869984121 @default.
• W4386998412 hasConcept C109316439 @default.
• W4386998412 hasConcept C126322002 @default.
• W4386998412 hasConcept C137061746 @default.
• W4386998412 hasConcept C153911025 @default.
• W4386998412 hasConcept C154317977 @default.
• W4386998412 hasConcept C159654299 @default.
• W4386998412 hasConcept C185592680 @default.
• W4386998412 hasConcept C202751555 @default.
• W4386998412 hasConcept C203014093 @default.
• W4386998412 hasConcept C2776090121 @default.
• W4386998412 hasConcept C2777701055 @default.
• W4386998412 hasConcept C2777726029 @default.
• W4386998412 hasConcept C2911091166 @default.
• W4386998412 hasConcept C40677261 @default.
• W4386998412 hasConcept C502942594 @default.
• W4386998412 hasConcept C542903549 @default.

• next